Yonsei University: Carcinoma, Ovarian Epithelial trials

The registry lists 10 Carcinoma, Ovarian Epithelial studies with Yonsei University as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 2 4No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian CancerRecruitingNCT05444270Not applicable
• Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay.CompletedNCT05504174
• Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Status unknownNCT05458973
• Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorStatus unknownNCT04734665Phase 2
• A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
• An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2
• Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian CancerStatus unknownNCT03618706Phase 2
• Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant ChemotherapyCompletedNCT03491033
• Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerCompletedNCT03367182
• The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical TrialCompletedNCT02135523Not applicable